Skip to main content

Basel Area treads unique path

Domenico Scala
| News

Basel Area treads unique path


Basel Area Business & Innovation is responsible for both location and innovation promotion. This approach, which is unique across Switzerland, is very successful according to Domenico Scala in a media interview. The president of Basel Area Business & Innovation also discusses future technologies such as digital health and mRNA.

Domenico Scala
Domenico Scala, President of the board of Basel Area Business & Innovation

The Basel Area is the most important life sciences location in Europe, says Domenico Scala in an interview with the HandelszeitungBasel Area Business & Innovation, the location and innovation promotion agency, plays a big part in this. Its work pursues an approach that is unique across Switzerland: linking location and innovation promotion. Scala says that the model works “very well. This means we are able to actively embed companies in the ecosystem while they are being established.”

Scala points to the fact that the Basel Area and the life sciences cluster near Boston play in the same league in terms of research. He adds that the University of Basel and the University Hospital contribute to this. “The Biozentrum at the University of Basel is one of the world’s leading centers for fundamental biomedical research. We have a subsidiary from the ETH Zürich, the Department of Biosystems, and we have several universities.” Scala mentions the Friedrich Miescher Institute and Novartis and Roche’s research facilities. “Around 1000 research groups are active in our region, a critical mass.”

In order for the location to remain strong in the future, engagement in pioneering areas is needed. According to Scala, one of these areas is the digitization of healthcare. “Others are further with this, not just the USA but also other European countries such as Finland and Denmark. Something needs to happen.” Basel Area Business & Innovation is already moving forward with its own initiatives. Scala adds that mRNA is also “an important future technology”. The technology has received support amounting to 50 million Swiss francs from the federal government. However, Scala thinks it is problematic to fund individual projects. Instead, he would like pension funds to be involved in funding startups. “Up to now, only a few tenths of a percent of pension fund assets are invested in venture capital. This needs to change. The money is there, we just need to make sure it is invested correctly.”

From the interview that Sreaina Ursina Gross from the “Handelszeitung” led with Domenico Scala:

The life sciences are an industry of the future, and we are far from exhausting our potential. There are skeptics who say we have a cluster risk.

You see it differently.

If anything, it's a cluster opportunity. Healthcare is the growth industry par excellence. That's because of the demographics, the growth of the middle class in developing countries, and technological advances. We are in a super cycle. Whether it's Basel, Zurich, Zug or Lausanne with the ETH is irrelevant. Of course, in a federal system, there is always some competition for jobs and talent. Everyone is fighting for their tax base. And that's the way it should be. But basically it's good that we have several locations. It makes us stronger in global competition.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.